API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.biopharmadive.com/news/takeda-stop-production-natpara-hypoparathyroidism/633295/
https://www.fiercepharma.com/pharma/hemophilia-rivalry-pressures-post-shire-takeda-but-ceo-weber-points-to-14-drugs-for-growth
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-2-2019-1570003052.pdf
https://www.fiercepharma.com/pharma/rhetoric-or-a-real-threat-track-weekly-drug-pricing-developments-us
https://www.fiercepharma.com/manufacturing/takeda-recalls-eye-drug-natpara-but-warns-patients-not-to-abruptly-stop-treatment
https://www.pharmacompass.com/pdf/news/takeda-issues-us-recall-of-natpara-parathyroid-hormone-1568769281.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511
https://www.bloomberg.com/news/articles/2018-09-13/takeda-is-said-to-weigh-sale-of-shire-eye-care-drug-to-cut-debt
https://www.cnbc.com/2018/09/13/reuters-america-takeda-weighs-sale-of-shires-eye-care-business-to-cut-debt-bloomberg.html